×
Researchers gain insight into factors influencing immunotherapy response in kidney cancer
https://www.healio.com/news/hematology-oncology/20200710/researchers-gain-insight-into-factors-influencing-immunotherapy-response-in-kidney-cancer

Jul 9th, 2020 - Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy. PD-1 checkpoint inhibitors such as pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb) have been shown to be more effective in treating tumors with high mutational burden. However, despite having only a moderate number of mutations, advanced clear cell ren...

Expert Perspective on ASCO20 Quality Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200237/full/

Jul 6th, 2020 - This essential study (Abstract 2003) highlights that health policy impacts cancer survival. It showed that age-adjusted mortality from cancer is worse in states that have not expanded access to Medicaid under the Affordable Care Act. There were 758 fewer cancer deaths in expansion states in 2017, and Hispanic populations had the greatest decrease in mortality under Medicaid expansion. This stud...

Expert Perspectives on the ASCO20 Plenary Session
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200236/full/

Jul 5th, 2020 - The JAVELIN Bladder 100 study (LBA1) investigated the efficacy of maintenance avelumab following platinum-based chemotherapy compared to best supportive care for patients with metastatic urothelial cancer. In the trial, avelumab improved median overall survival by 21.4 months compared to 14.3 months with best supportive care. These data are practice changing, and the degree of benefit to this a...

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

Olaparib shows 1-year survival benefit in recurrent ovarian cancer, BRCA mutations
https://www.healio.com/news/hematology-oncology/20200707/olaparib-shows-1year-survival-benefit-in-recurrent-ovarian-cancer-brca-mutations

Jul 6th, 2020 - Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Retreatment with CAR-T therapy shows clinical efficacy in lymphoma
https://www.healio.com/news/hematology-oncology/20200708/retreatment-with-cart-therapy-shows-clinical-efficacy-in-lymphoma

Jul 7th, 2020 - In a small sample, retreatment of patients with large B-cell lymphoma showed good response, notably in patients who had complete response on initial treatment, according to a poster presented at ASCO 2020 Virtual Scientific Program.

Patient survival greatly impacted by selection for ovarian cancer relapse surgery
https://www.healio.com/news/hematology-oncology/20200707/patient-survival-greatly-impacted-by-selection-for-ovarian-cancer-relapse-surgery

Jul 6th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Dual target CAR T-cell therapy effective, durable, less toxic in lymphoma
https://www.healio.com/news/hematology-oncology/20200706/dual-target-car-tcell-therapy-effective-durable-less-toxic-in-lymphoma

Jul 5th, 2020 - A novel CAR T-cell therapy targeting both CD19 and CD22 showed less toxicities than current CAR T-cell therapies while producing complete response with accepted regimens, according to a study presented at ASCO2020 Virtual Scientific Program.

Avelumab ‘opens up the door’ for immunotherapy in trophoblastic disease
https://www.healio.com/news/hematology-oncology/20200707/avelumab-opens-up-the-door-for-immunotherapy-in-trophoblastic-disease

Jul 6th, 2020 - A study presented during the ASCO2020 Virtual Scientific Program showed ‘impressive’ use of immunotherapy for gestational trophoblastic disease, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Expert Perspective on ASCO20 Genitourinary Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200232/full/

Jul 2nd, 2020 - The phase III HERO trial (Abstract 5602) investigated the results of relugolix, an orally bioavailable GnRH receptor antagonist, for patients with advanced prostate cancer. Treatment with relugolix resulted in superiority over leuprolide in achieving sustained testosterone suppression. Additionally, treatment was associated with faster testosterone recovery and decreased major adverse cardiovas...

Expert Perspective on ASCO20 Gynecologic Oncology Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200233/full/

Jul 2nd, 2020 - DESKTOP III (Abstract 6000) is a prospective, multicenter, randomized phase III study of > 400 patients with platinum-sensitive, recurrent ovarian cancer that demonstrated a clinically meaningful 7.7 month improvement in median overall survival with secondary cytoreductive surgery (53.7 months) compared with no surgery (46 months).

Immunotherapy and Beyond: Treatment Options and Potential Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200227/full/

Jul 2nd, 2020 - Head and neck cancers account for approximately 4% of all cancers in the United States1 and are the eighth most common cancer affecting men in the United States.2 The diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) carries a poor prognosis, with an overall survival (OS) of approximately 1 year.

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-cell therapy, with 4-1BB costimulatory domain and CD3Z T-cell activation domain.

Expert Perspective on ASCO20 Gastrointestinal Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200231/full/

Jul 1st, 2020 - Donafenib, a deuterated derivative of sorafenib, was tested against sorafenib in the frontline setting in hepatitis B– associated hepatocellular carcinoma (HCC) in a large, multi-institutional study in China (Abstract 4506).

Breast Cancer Research at ASCO20 Virtual Scientific Program Highlights New Avenues and Better Outcomes
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200222/full/

Jun 24th, 2020 - The ASCO20 Virtual Scientific Program featured a variety of important and innovative breast cancer research. The following are some of the studies with potential to significantly impact clinical practice and patient outcomes, as selected by ASCO Daily News Expert Panel member Arielle Heeke, MD, of the Levine Cancer Institute.

Top Lung Cancer Research Presented at the ASCO20 Virtual Scientific Program Has Implications for Clinical Practice
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200223/full/

Jun 24th, 2020 - Although the ASCO Annual Meeting felt much different this year given the virtual format, the quality of research presented at the meeting was undiminished, particularly in the field of lung cancer. ASCO Daily News Expert Panel member Jared Weiss, MD, of the University of North Carolina School of Medicine, reviewed the most influential lung cancer research presented during the ASCO20 Virtual Sci...

ECOG-ACRIN Trial Reassures Clinicians, Patients That Locoregional Therapy Is Not Beneficial for Stage IV Metastatic Breast Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200218/full/

Jun 23rd, 2020 - For patients with stage IV metastatic breast cancer and an intact primary tumor (ITP), the early initiation of locoregional treatment (LRT) was not associated with longer survival or improvements in health-related quality of life (HRQoL) compared with systemic therapy alone, according to a phase III clinical trial (Abstract LBA2). These findings appear to add to a robust evidence base that sugg...

Switch Maintenance With Avelumab Changes Treatment Paradigm for Advanced Urothelial Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200217/full/

Jun 23rd, 2020 - A switch maintenance therapy approach using the immune checkpoint inhibitor avelumab in patients with advanced urothelial carcinoma (UC) who had not progressed after induction platinum-based chemotherapy offered significantly improved survival outcomes, according to results of the JAVELIN Bladder 100 trial (Abstract LBA1). The study, which was the first UC study ever presented during an ASCO An...

Will DFS Benefit Translate Into Survival Benefit in ADAURA?
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200221/full/

Jun 23rd, 2020 - The report on ADAURA during the ASCO20 Virtual Scientific Program Plenary Session surprised many, first because the initial data readout for the phase III trial was not planned until 2022 and second because of the strength of the disclosed data (Abstract LBA5). Early unblinding of the results revealed an 83% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib c...

Clinical Implications of First-Line Pembro for MSI-High mCRC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200220/full/

Jun 23rd, 2020 - Long-awaited results from the randomized, phase III KEYNOTE-177 trial provide strong support for using single-agent pembrolizumab instead of a chemotherapy-based regimen in patients newly diagnosed with metastatic colorectal cancer (mCRC) featuring high-level microsatellite instability (MSI-H) or deficient mismatch repair (dMMR; Abstract LBA4).

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200219/full/

Jun 23rd, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or intermediate-risk multiple myeloma (Abstract LBA3). KRd failed to improve progression-free survival compared with VRd, according to data presented by Shaji K...

Trastuzumab Achieves Slight Reduction in Recurrence for Women With HER2-Positive DCIS
https://ascopost.com/news/june-2020/trastuzumab-achieves-slight-reduction-in-recurrence-for-women-with-her2-positive-dcis/

Jun 7th, 2020 - The addition of trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) in the NRG Oncology clinical trial NSABP B-43. The trial did find a modest (19%) reduction in the rate of recurrence among women who received trastuzumab, but this difference was not stati...

Remote Pre- and Posttest Genetic Counseling for Breast and Ovarian Cancer Risk
https://ascopost.com/news/june-2020/remote-pre-and-post-test-genetic-counseling-for-breast-and-ovarian-cancer-risk/

Jun 1st, 2020 - Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don't get tested. A collaborative team of researchers have tested a possible solution through a clinical trial aimed at making genetic testing more accessible. The trial, called MAGENTA (Making GENetic Testing Accessi...

Androgen Deprivation With Oral Relugolix vs Leuprolide in Advanced Prostate Cancer: HERO Trial
https://ascopost.com/news/june-2020/androgen-deprivation-with-oral-relugolix-vs-leuprolide-in-advanced-prostate-cancer-hero-trial/

Jun 3rd, 2020 - As reported at the ASCO20 Virtual Scientific Program (Abstract 5602) and in The New England Journal of Medicine by Shore et al, the phase III HERO trial showed sustained castrate testosterone levels and lower risk of major cardiovascular events with the oral gonadotropin-releasing hormone antagonist relugolix given daily vs the injectable luteinizing hormone–releasing hormone agonist leuprolide...

Cediranib/Olaparib vs Standard-of-Care Chemotherapy for Platinum-Sensitive Ovarian Cancer
https://ascopost.com/news/june-2020/cediranibolaparib-vs-standard-of-care-chemotherapy-for-platinum-sensitive-ovarian-cancer/

Jun 1st, 2020 - Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes for women with platinum-sensitive ovarian cancer; however, activity between the treatments was similar in patients. These results were recently presented by Joyce ...

Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer
https://ascopost.com/news/june-2020/final-overall-survival-analysis-of-the-prosper-trial-in-nonmetastatic-castration-resistant-prostate-cancer/

Jun 1st, 2020 - In the final overall survival analysis of the phase III PROSPER trial reported at the ASCO20 Virtual Scientific Program (Abstract 5515) and published in The New England Journal of Medicine, Cora N. Sternberg, MD, and colleagues found that enzalutamide plus androgen-deprivation therapy (ADT) significantly improved overall survival vs placebo plus ADT in men with nonmetastatic castration-resistan...

Results From an Oncology Hospital-at-Home Evaluation
https://ascopost.com/news/june-2020/results-from-an-oncology-hospital-at-home-evaluation/

Jun 4th, 2020 - Researchers at Huntsman Cancer Institute (HCI) at the University of Utah presented the first outcomes evaluation of an adult oncology hospital-at-home program during the ASCO20 Virtual Scientific Program (Abstract 7000). The study evaluated patients participating in HCI's Huntsman at Home program. The data demonstrated strong evidence for the benefits of this care model, showing improved patien...

RET Kinase Inhibitor for Patients With Solid Tumors and RET Genetic Fusions
https://ascopost.com/news/june-2020/ret-kinase-inhibitor-for-patients-with-solid-tumors-and-ret-genetic-fusions/

Jun 4th, 2020 - The RET inhibitor pralsetinib showed activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the phase I/II ARROW trial, presented by Vivek Subbiah, MD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 109).

Richard L. Schilsky, MD, on This Year’s Practice-Changing Findings
https://ascopost.com/videos/asco20-virtual-scientific-program/richard-schilsky-on-this-year-s-practice-changing-findings/

May 29th, 2020 - Richard L. Schilsky, MD, Chief Medical Officer of ASCO, talks about some of the most important and practice-changing findings presented this year at the ASCO20 Virtual Scientific Program, including the use of targeted and immunotherapies in earlier lines of therapy, where they have made a significant impact.

Michael S. Hofman, MBBS, on Prostate Cancer: LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/michael-hofman-on-lupsma-vs-cabazitaxel-in-metastatic-castration-resistant-prostate-cancer/

May 29th, 2020 - Michael S. Hofman, MBBS, of the Peter MacCallum Cancer Centre, discusses phase II results from the ANZUP 1603 trial, which showed that in men with docetaxel-treated metastatic castration-resistant prostate cancer, LuPSMA was more active than cabazitaxel, with relatively fewer grade 3 and 4 adverse events and a more favorable PSA progression-free-survival (Abstract 5500).

David R. Wise, MD, PhD, on Novel Biomarkers in Prostate Cancer: Is Tissue the Issue?
https://ascopost.com/videos/asco20-virtual-scientific-program/david-wise-on-novel-biomarkers-in-prostate-cancer/

May 29th, 2020 - David R. Wise, MD, PhD, of New York University Perlmutter Cancer Center, summarizes three important studies in prostate cancer: circulating tumor cell count as a prognostic marker of PSA response and progression in metastatic castration-sensitive disease; new phenotypic subtypes; and how circulating tumor DNA dynamics associate with treatment response and radiologic progression-free survival (A...

Is Sentinel Lymph Node Biopsy Alone Oncologically Safe for Patients With Early-Stage Cervical Cancer?
https://ascopost.com/news/may-2020/is-sentinel-lymph-node-biopsy-alone-oncologically-safe-for-patients-with-early-stage-cervical-cancer/

May 29th, 2020 - In a study of patients with early-stage cervical cancer presented by Balaya et al during the Gynecologic Cancer Oral Abstract Session of the ASCO20 Virtual Scientific Program (Abstract 6006), researchers assessed disease-free and disease-specific survival to determine whether sentinel lymph node biopsy alone was a valid standard of care, or if bilateral pelvic lymphadenectomy—the current “gold ...

Scott Kopetz, MD, PhD, on Colorectal Cancer: Encorafenib Plus Cetuximab With or Without Binimetinib
https://ascopost.com/videos/asco20-virtual-scientific-program/scott-kopetz-on-encorafenib-plus-cetuximab-with-or-without-binimetinib-in-colorectal-cancer/

May 29th, 2020 - Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results of the BEACON CRC study, which confirmed that, compared with standard chemotherapy, encorafenib plus cetuximab with or without binimetinib improved overall survival and objective response rate in previously treated patients with BRAF V600E–mutated metastatic colorectal cancer (Abstract 4001).

David C. Fajgenbaum, MD, MBA, on Chasing His Cure: A Physician Is Battling His Disease and Beating the Odds
https://ascopost.com/videos/asco20-virtual-scientific-program/david-fajgenbaum-on-chasing-his-cure-for-castleman-disease/

May 29th, 2020 - David C. Fajgenbaum, MD, MBA, of the University of Pennsylvania, who trained as an oncologist, summarizes his opening lecture, a dramatic story of his battle against Castleman, a disease of the lymph nodes, his multiple near-death experiences, and the path that led him to develop a cooperative research effort making a difference for him and other patients with this idiopathic orphan illness.

Welcome to This Year’s Meeting: A Message From ASCO President Howard A. Burris III, MD, FACP, FASCO
https://ascopost.com/videos/asco20-virtual-scientific-program/a-message-from-asco-president-howard-burris/

May 29th, 2020 - Howard A. Burris III, MD, FACP, FASCO, President of ASCO, talks about what to expect from this year’s ASCO20 Virtual Scientific Program and its many offerings.

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

HIF2A Inhibitor for von Hippel-Lindau Disease–Associated Renal Cell Carcinoma
https://ascopost.com/news/may-2020/hif2a-inhibitor-for-von-hippel-lindau-disease-associated-renal-cell-carcinoma/

May 29th, 2020 - In an international trial, treatment with MK-6482, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease–associated renal cell carcinoma (RCC).

Merry-Jennifer Markham, MD: Perspectives on Three Abstracts From the ASCO Cancer Communications Chair
https://ascopost.com/videos/asco20-virtual-scientific-program/merry-jennifer-markham-perspectives-on-three-abstracts/

May 29th, 2020 - Merry-Jennifer Markham, MD, ASCO’s Cancer Communications Chair, gives her views on key papers presented at the ASCO20 Virtual Scientific Program, addressing gynecologic malignancies and COVID-19.

Fatima Cardoso, MD, on Breast Cancer: MammaPrint as Guidance for Adjuvant Chemotherapy
https://ascopost.com/videos/asco20-virtual-scientific-program/fatima-cardoso-on-mammaprint-as-guidance-for-adjuvant-chemotherapy/

May 29th, 2020 - Fatima Cardoso, MD, of Lisbon’s Champalimaud Cancer Center, discusses the long-term results of MINDACT, a large prospective trial showing the clinical utility of the 70-gene signature MammaPrint for adjuvant chemotherapy decision-making. The primary distant metastasis–free survival endpoint at 5 years continued to be met in chemotherapy-untreated women with clinical-high/genomic-low risk diseas...

Data From TAPUR Study Cohorts on Olaparib for BRCA-Mutated Advanced Prostate and Pancreatic Cancers
https://ascopost.com/news/may-2020/data-from-tapur-study-cohorts-on-olaparib-for-brca-mutated-advanced-prostate-and-pancreatic-cancers/

May 29th, 2020 - Positive results from two cohorts of the Targeted Agent and Profiling Utilization Registry (TAPUR) study provide real-world evidence to support recent clinical trial data that demonstrate a role for olaparib in the treatment of advanced prostate and pancreatic cancers with BRCA1/2-inactivating mutations. The findings were presented during the ASCO20 Virtual Scientific Program (Abstract 5567, Ab...

Tepotinib Shows Activity in Patients With NSCLC and MET Exon 14–Skipping Mutation
https://ascopost.com/news/may-2020/tepotinib-shows-activity-in-patients-with-nsclc-and-met-exon-14-skipping-mutation/

May 28th, 2020 - Patients with advanced non–small cell lung cancer (NSCLC) and a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study presented during the ASCO20 Virtual Scientific Program (Abstract 9556) and published simultaneously by Paik et al in The New England Journal of Medicine.

Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Celecoxib and FOLFOX for Stage III Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/jeffrey-meyerhardt-on-celecoxib-and-folfox-for-stage-iii-colon-cancer/

May 29th, 2020 - Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the CALGB/SWOG 80702 trial of celecoxib plus standard adjuvant therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX). Adding celecoxib to standard chemotherapy did not significantly improve disease-free or overall survival (Abstract 4003).

Transoral Resection Followed by Low-Dose Radiation for Some Oropharyngeal Cancers
https://ascopost.com/news/may-2020/transoral-resection-followed-by-low-dose-radiation-for-some-oropharyngeal-cancers/

May 29th, 2020 - The final results of the randomized phase II ECOG-ACRIN E3311 trial were presented by Robert L. Ferris, MD, PhD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 6500) and in today's Head and Neck Cancer Oral Abstract Session. The trial, conducted in patients undergoing transoral robotic surgery, tested reduced postoperative radiation therapy in patients with human papillom...

First-Line Pembrolizumab Plus Etoposide/Platinum for Extensive-Stage Small Cell Lung Cancer
https://ascopost.com/news/may-2020/first-line-pembrolizumab-plus-etoposideplatinum-for-extensive-stage-small-cell-lung-cancer/

May 29th, 2020 - As reported at the ASCO20 Virtual Scientific Program by Charles M. Rudin, MD, PhD, and colleagues (Abstract 9001), the phase III KEYNOTE-604 trial has shown that first-line pembrolizumab plus etoposide/platinum significantly prolonged progression-free survival and prolonged overall survival at a near significant level vs placebo plus etoposide/platinum in patients with extensive-stage small cel...

Shaji Kumar, MD, on Multiple Myeloma: Phase III Results on Carfilzomib, Lenalidomide, Bortezomib, and Dexamethasone
https://ascopost.com/videos/asco20-virtual-scientific-program/shaji-kumar-on-carfilzomib-lenalidomide-bortezomib-and-dexamethasone-in-multiple-myeloma/

May 29th, 2020 - Shaji Kumar, MD, of the Mayo Clinic, discusses findings from the ENDURANCE trial, which showed bortezomib, lenalidomide, and dexamethasone should remain the standard of care in patients with newly diagnosed standard- or intermediate-risk multiple myeloma, for whom early autologous stem cell transplant is not intended (Abstract LBA3).

Nancy U. Lin, MD, on Metastatic Breast Cancer: Tucatinib, Trastuzumab, and Capecitabine
https://ascopost.com/videos/asco20-virtual-scientific-program/nancy-lin-on-tucatinib-trastuzumab-and-capecitabine-for-metastatic-breast-cancer/

May 29th, 2020 - Nancy U. Lin, MD, of Dana-Farber Cancer Institute, discusses the HER2CLIMB study of patients with previously treated HER2-positive metastatic breast cancer that had metastasized to the brain. Adding tucatinib to trastuzumab and capecitabine doubled the intracranial response rate and reduced the risk of death by nearly half, compared with trastuzumab plus capecitabine (Abstract 1005).

Intensive Remote Monitoring of High-Risk Patients Initiating Antineoplastic Treatment
https://ascopost.com/news/may-2020/intensive-remote-monitoring-of-high-risk-patients-initiating-antineoplastic-treatment/

May 29th, 2020 - As reported at the ASCO20 Virtual Scientific Program by Robert Michael Daly, MD, MBA, and colleagues (Abstract 2027), use of a pilot program of intensive remote monitoring of high-risk outpatients receiving antineoplastic treatment has shown considerable promise in the ability to improve patient care and decrease use of hospital resources by promptly alerting practitioners to symptoms that requ...

Precision Medicine on a Large Scale for Pediatric Patients With Cancer
https://ascopost.com/news/may-2020/precision-medicine-on-a-large-scale-for-pediatric-patients-with-cancer/

May 28th, 2020 - Although 84% of children with cancer survive 5 years or more, children with refractory, relapsed, and progressive high-risk malignancies have a poor median survival of 9.5 months. The German INFORM registry is a large prospective, noninterventional, multicenter study collecting clinical and molecular data on pediatric patients with refractory, relapsed, and progressive malignant cancers. The st...

Patients With Cancer—Especially Progressive Disease—Infected With COVID-19 May Have an Increased Risk of Death
https://ascopost.com/news/may-2020/patients-with-cancer-especially-progressive-disease-infected-with-covid-19-may-have-an-increased-risk-of-death/

May 28th, 2020 - A large cohort study by the COVID-19 and Cancer Consortium evaluating the impact of COVID-19 on patients with cancer has found that all-cause 30-day mortality and severe illness were significantly higher in this population than previously reported in the general population. Mortality and severe illness were associated with general risk factors, as well as those unique to patients with cancer, a...

Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization
https://ascopost.com/news/may-2020/study-finds-patients-with-lung-cancer-infected-with-covid-19-recently-treated-with-chemotherapy-at-higher-risk-of-death/

May 28th, 2020 - Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was the use of steroids or anticoagulants. Prior administration of immunotherapy and chemoimmunotherapy ...

Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib in Stage Ib–IIIa EGFR Mutation–Positive Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/roy-herbst-on-osimertinib-in-stage-ib-iiia-egfr-mutation-positive-nsclc/

May 29th, 2020 - Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses data from the ADAURA study, which showed that compared with placebo, osimertinib as adjuvant therapy after complete tumor resection reduced the risk of disease recurrence or death by 79% in patients with non–small cell lung cancer (Abstract LBA5).

Christopher Sweeney, MBBS, and Thomas Powles, MD, PhD, on Urothelial Cancer: The JAVELIN Bladder 100 Study on Avelumab vs Best Supportive Care
https://ascopost.com/videos/asco20-virtual-scientific-program/christopher-sweeney-and-thomas-powles-on-avelumab-vs-best-supportive-care-in-urothelial-cancer/

May 29th, 2020 - Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, talks with Thomas Powles, MD, PhD, of Queen Mary University of London, about the first study to demonstrate a survival advantage with avelumab for metastatic urothelial cancer. In the trial, avelumab improved median overall survival by 21.4 months compared with 14.3 months with best supportive care (Abstract LBA1).

New Data Support Debulking to Prolong Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200180/full/

May 28th, 2020 - DESKTOP III became the first phase III, prospective, randomized trial to show an association between improved overall survival (OS) and secondary cytoreductive surgery in women with platinum-sensitive recurrent ovarian cancer (PSROC), offering hope for people with a condition that results in nearly 14,000 deaths annually. Data were presented during the ASCO20 Virtual Scientific Program (Abstrac...

Palliative Care Improves Well-Being and QoL in Phase I Cancer Trial Participants
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200184/full/

May 28th, 2020 - Participants in phase I oncology trials represent a patient population new to palliative care. These patients typically have remarkable symptoms, with a symptom burden comparable to other patients with cancer.1 Thomas J. Smith, MD, FASCO, of Johns Hopkins University, presented the results of a randomized trial evaluating a palliative care intervention (PCI) compared with usual care (UC) for pat...

Effect of Veliparib With or Without Cisplatin in Breast Cancer: Results of SWOG S1416
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200176/full/

May 28th, 2020 - The Southwest Oncology Group (SWOG) 1416 phase II trial was designed to compare the efficacy of the PARP inhibitor veliparib plus cisplatin versus cisplatin alone in patients with metastatic and/or locally recurrent triple-negative breast cancer (TNBC) or BRCA1 or BRCA2 germline mutation–associated HER2-negative metastatic breast cancer. Priyanka Sharma, MD, of the University of Kansas Medical ...

Pembrolizumab Monotherapy Demonstrates PFS Benefit Over Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200193/full/

May 28th, 2020 - Pembrolizumab monotherapy demonstrated a progression-free survival (PFS) benefit over brentuximab vedotin (BV) in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma, according to the results from the phase III international KEYNOTE-204 trial (Abstract 8005). Clinically meaningful improvement in PFS was observed in all subgroups tested, including patients who did not receive a...

Sentinel Node Biopsy Strategy Equivalent to Neck Dissection in T1-T2NO Oropharyngeal and Oral Cancers
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200192/full/

May 28th, 2020 - In a randomized multicenter study, a strategy based on sentinel node biopsy (SNB) was equivalent to elective neck dissection (END) in the management of T1-T2N0 oral and oropharyngeal squamous cell carcinomas, with comparable 2-year neck recurrence-free survival (RFS) and lower morbidity in year 1 after surgery (Abstract 6501). Renaud Garrel, MD, of CHU Montpellier, France, presented the results...

Selinexor/Bortezomib/Dexamethasone Triplet Improves PFS, ORR in Multiple Myeloma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200181/full/

May 28th, 2020 - Once-weekly selinexor, bortezomib, and dexamethasone (SVd) for relapsed/refractory multiple myeloma (MM) significantly improved progression-free survival (PFS) and overall response rate (ORR) when compared with twice-weekly bortezomib and dexamethasone (Vd), according to initial results from the phase III BOSTON trial (Abstract 8501).

KarMMa: BCMA-Targeting CAR T Excellent Option for Relapsed/Refractory Myeloma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200194/full/

May 28th, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) resulted in deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to phase II data from the KarMMa trial (Abstract 8503).

Early Data Show Bispecific Antibody Teclistamab Safe, Active in Relapsed/Refractory Multiple Myeloma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200175/full/

May 28th, 2020 - Teclistamab, a IgG-4 bispecific antibody targeting BCMA and CD3, appears to be safe in patients with relapsed or refractory multiple myeloma, according to phase I data presented during the ASCO20 Virtual Scientific Program (Abstract 100).

Donafenib Improves OS in Hepatocellular Carcinoma Compared With Sorafenib
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200179/full/

May 28th, 2020 - Donafenib significantly improved overall survival (OS) rates compared with sorafenib in patients with hepatocellular carcinoma (HCC) and did so with favorable safety and tolerability, according to a new study (Abstract 4506).

Low Muscle Density Associated With Symptoms, Health Care Use, and Survival in Advanced Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200169/full/

May 28th, 2020 - Muscle mass (quantity) is highly correlated with survival in hospitalized patients with advanced cancer, whereas muscle density (quality) is associated with patients’ symptoms, health care use, and survival, according to a group of researchers (Abstract 7006).

ADJUVANT-CTONG 1104 Results Underscore the Value of Using EGFR-Targeted Therapy in EGFR-Mutated NSCLC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200182/full/

May 28th, 2020 - During the 2017 ASCO Annual Meeting, investigators of the ADJUVANT-CTONG 1104 trial first reported that postsurgical treatment with gefitinib conferred a significant 10.7-month improvement in disease-free survival (DFS) compared with standard doublet chemotherapy in patients with stage II-IIIA EGFR-positive non–small cell lung cancer (NSCLC), thus meeting the primary study endpoint (HR 0.60, 95...

Trastuzumab Fails to Improve DFS When Added to Trimodality Therapy for Operable Esophageal Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200178/full/

May 28th, 2020 - Although HER-targeted therapy represents a standard of care for many HER2-positive malignancies, data supporting its benefit for patients with early-stage HER2-overexpressing esophageal adenocarcinoma are lacking. Results of the RTOG 1010 trial demonstrated that adding trastuzumab both before and after chemoradiotherapy and surgery did not significantly improve disease-free survival (DFS) beyon...

Final IDEA Collaboration Results Support Just 3 Months of Adjuvant CAPOX for Most Patients With Stage III Colon Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200177/full/

May 28th, 2020 - Prospective evaluation of nearly 13,000 individuals with stage III colon cancer found minimal difference in 5-year overall survival (OS) with 3 versus 6 months of adjuvant CAPOX or FOLFOX for the majority of patients, according to the final results of the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration (Abstract 4004). In contrast, the shorter treatment course pr...

Dr. Sondos Zayed Receives the Philip Francis Mulvey, III, Endowed Merit Award for Research on Opioid Addiction Risk in Patients With Head and Neck Cancer
https://dailynews.ascopubs.org/do/10.5555/ADN.20.200185/full/

May 28th, 2020 - A new merit award memorializing a remarkable man’s lifetime mission of mentorship is honoring a particularly appropriate inaugural recipient—Sondos Zayed, MD, an early-career resident clinical investigator at Western University, Canada.

Three Years of Imatinib Improves OS in High-Risk Operable GIST
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/

May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/German trial (Abstract 11503).

Triplet Combination Considered New Standard of Care for Patients With HER2-Positive Metastatic Breast Cancer, Brain Metastases
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200164/full/

May 28th, 2020 - Exploratory analyses conducted in a subset of heavily pretreated patients with brain metastases enrolled on the HER2CLIMB trial found that tucatinib in combination with trastuzumab and capecitabine reduces the risk of intracranial (IC) progression and death in patients with HER2-positive metastatic breast cancer (MBC; Abstract 1005). Nancy U. Lin, MD, of Dana-Farber Cancer Institute, presented ...

Upfront Radiation Added to TKI Therapy Improves Outcomes in Oligometastatic NSCLC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200171/full/

May 28th, 2020 - The addition of stereotactic body radiation therapy (SBRT) to tyrosine kinase inhibitor (TKI) therapy yielded longer progression-free survival (PFS) and overall survival (OS) than TKI therapy alone in patients with EGFR-mutant oligometastatic non–small cell lung cancer (NSCLC), according to an interim analysis of an open-label phase III trial presented during the ASCO20 Virtual Scientific Progr...

Palliative Care Improves Quality of Life in Patients With AML
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200172/full/

May 28th, 2020 - When patients with acute myeloid leukemia (AML) undergo intensive chemotherapy treatment, their quality of life (QoL) and mood are negatively affected. Areej El-Jawahri, MD, of Massachusetts General Hospital, presented the results of a multicenter study conducted in patients with AML to determine if integrated palliative and oncology care could improve QoL and other important aspects of patient...

T-DM1 Does Not Improve Safety or Efficacy in HER2-Positive Early Breast Cancer; Favorable iDFS Reported
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200162/full/

May 28th, 2020 - Findings from the primary analysis of the KAITLIN trial suggest that replacement of adjuvant taxane with trastuzumab emtansine (T-DM1) does not improve survival or safety for patients with HER2-positive early-stage breast cancer (Abstract 500). However, both treatments demonstrated outstanding long-term invasive disease–free survival (iDFS) in a high-risk population. Study author Nadia Harbeck,...

18F-DCFPyL–PET/CT Imaging Improves Diagnostic Capability in Relapsed Prostate Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200168/full/

May 28th, 2020 - Imaging with 18F-DCFPyL–PET/CT was found to be diagnostically effective, often guiding a change in treatment plan, in men with biochemically relapsed prostate cancer, according to the results of the phase III CONDOR study presented during the ASCO20 Virtual Scientific Program (Abstract 5501).

Apalutamide, Darolutamide, Enzalutamide Yield OS Benefit in nmCRPC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200161/full/

May 28th, 2020 - Final survival results from three randomized, placebo-controlled trials, along with a safety analysis across all three, are helping to clarify the treatment landscape for nonmetastatic castration-resistant prostate cancer (nmCRPC). The results will be presented during the ASCO20 Virtual Scientific Program.

Strategies Emerge for Chemotherapy De-escalation in HER2-Positive Breast Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200163/full/

May 28th, 2020 - Two studies presented during the ASCO20 Virtual Scientific Program show the potential to de-escalate chemotherapy in the setting of dual HER2 blockade for patients with HER2-positive breast cancer.

Integrated Oncogeriatric Care Improves Health-Related Quality of Life
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200173/full/

May 28th, 2020 - Integrated oncogeriatric care led to improvements in health-related quality of life (HRQoL), unplanned hospital admissions, and treatment discontinuation in older people receiving systemic anticancer therapy, according to a study presented during the ASCO20 Virtual Scientific Program (Abstract 12011).

VDC/IE Regimen Yields Improved Outcomes Over VIDE in Ewing’s Sarcoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200154/full/

May 28th, 2020 - A randomized trial found that for patients with newly diagnosed Ewing’s sarcoma, a chemotherapy regimen consisting of vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide (VDC/IE) offers better event-free survival (EFS) and overall survival (OS) than a regimen of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE; Abstract 11500).